Affinity Asset Advisors, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001773195

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 112 positions · Total reported value $2.15B · Top-10 concentration 46.3% · Updated 2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

Turnover: 55.3% · 24 new · 29 cut · 20 exited

Active Share (vs S&P 500): 99.9% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -12.1% · vs SPY -14.3% · Prev Value $2.08B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -2.2% · vs SPY -4.3% · Latest Value $2.15B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Affinity Asset Advisors, LLC disclosed 112 equity positions with a combined reported value of $2.15B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 46.3% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were IWM ($277.89M), ROIV ($117.02M), SYRE ($113.88M). By sector, the heaviest allocations are Health Care 80.5%, Financials 1.4%. Versus the prior quarter, allocation shifted toward Other (+7.1pp) and away from Health Care (-7.1pp).

Versus the prior quarter, Affinity Asset Advisors, LLC opened 24 new positions, trimmed 29 and fully exited 20, a turnover rate of 55.3% of positions. The portfolio's overlap with the prior quarter was 67% of names.

The largest new positions opened in Q3 2026 were IWM ($277.89M), XBI ($94.61M), ARVN ($15.86M).

Of the 20 positions fully exited versus the prior quarter, the largest were APGE ($131.00M), NUVL ($33.96M), FBRX ($24.34M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • IWM ISHARES TR · $277.89M
  • XBI SPDR SERIES TRUST · $94.61M
  • ARVN ARVINAS INC · $15.86M
  • BEAM BEAM THERAPEUTICS INC · $11.00M
  • PRLD PRELUDE THERAPEUTICS INC · $10.17M
  • ANIX KORSANA BIOSCIENCES INC · $8.42M
  • AKTS AKTIS ONCOLOGY INC · $6.81M
  • SLN SILENCE THERAPEUTICS PLC · $4.92M

Fully Exited (vs previous quarter)

  • APGE APOGEE THERAPEUTICS INC · prev qtr: $131.00M
  • NUVL NUVALENT INC · prev qtr: $33.96M
  • FBRX FORTE BIOSCIENCES INC · prev qtr: $24.34M
  • LLY ELI LILLY & CO · prev qtr: $23.99M
  • TEVA TEVA PHARMACEUTICAL INDS LTD · prev qtr: $12.67M
  • QURE UNIQURE NV · prev qtr: $8.06M
  • ASND ASCENDIS PHARMA A/S · prev qtr: $8.00M
  • EVMN EVOMMUNE INC · prev qtr: $6.65M

Insider Transactions (Form 4)

Latest Affinity Asset Advisors, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Affinity Asset Advisors, LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 108 US equity positions with a combined value of $2.08B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-120744 (status: Approved), registered 2021-04-09
  • Regulatory AUM (Form ADV): $2.45B as of 2026-07-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 1 hedge funds
  • Website: affinityadv.com

Portfolio Structure

  • 108 positions · $2.08B reported value (Q2 2026)
  • Top 10 holdings = 41.7% of reported value
  • Largest position: ROIV (ROIVANT SCIENCES LTD) at 6.4%
  • Average position size: $19.25M

Sector Tilt

  • Health Care 87.6%
  • Financials 1.3%
  • Materials 0.3%
  • (classified holdings cover 89% of value)

Quarterly Activity

  • Q2 2026: 19 new, 34 added, 31 reduced, 12 exited
  • 24 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund expanded its portfolio (24 new positions, 112 total) with a strong tilt toward healthcare (80% of top-10 holdings), suggesting a bullish view on biotech/therapeutics. New ETF positions (IWM, XBI) indicate broader market exposure alongside sector-specific bets. 2. Key moves: - Added: TRAX (+1.46% wt), XENE (+1.66% wt), AVTX (+0.74% wt), ORKA (+0.37% wt), ERAS (+0.81% wt). - Reduced: ROIV (-0.93% wt), INSM (-0.33% wt). - New: IWM (12.94% wt), XBI (4.41% wt). 3. Portfolio structure: Active, healthcare-heavy (90% of top-10), with moderate risk (mix of high-growth biotechs and diversified ETFs). 4. Per-holding one-liner: - IWM: iShares Russell 2000 ETF (U.S. small-cap). - ROIV: Roviant Sciences (biopharma, unverified). - SYRE: Spyre Therapeutics (oncology, unverified). - XBI: SPDR S&P Biotech ETF (biotech sector). - ERAS: Erasca (cancer therapeutics, unverified). - TRAX: First Tracks Bio (immunotherapy, unverified). - XENE: Xenon Pharmaceuticals (pain therapeutics, unverified). - INSM: Insmed (infectious disease, unverified). - ORKA: Oruka Therapeutics (unverified). - AVTX: Avalo Therapeutics (respiratory disease, unverified). 5. Style summary: Aggressive healthcare-focused fund adding biotech/ETF exposure while trimming select positions.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-16 13:42

Sector Allocation

Health Care 80.5%
Financials 1.4%
Materials 0.2%
Other 18.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.00M $277.89M 12.94%
12.94%
New
2 3.20M $117.02M 5.45%
5.45%
Reduce
3 1.28M $113.88M 5.30%
5.30%
Hold
4 600.00K $94.61M 4.41%
4.41%
New
5 5.59M $81.96M 3.82%
3.82%
Add
6 2.08M $73.72M 3.43%
3.43%
Add
7 1.90M $70.67M 3.29%
3.29%
Add
8 564.25K $64.40M 3.00%
3.00%
Reduce
9 600.00K $49.97M 2.33%
2.33%
Add
10 3.24M $49.74M 2.32%
2.32%
Add
11 750.00K $49.43M 2.30%
2.30%
Add
12 250.00K $48.14M 2.24%
2.24%
Reduce
13 225.00K $46.18M 2.15%
2.15%
Reduce
14 155.00K $45.14M 2.10%
2.10%
Reduce
15 242.09K $41.11M 1.91%
1.91%
Add
16 1.16M $37.61M 1.75%
1.75%
Add
17 330.00K $32.68M 1.52%
1.52%
Hold
18 350.00K $30.82M 1.44%
1.44%
Reduce
19 1.70M $28.75M 1.34%
1.34%
Add
20 1.26M $28.00M 1.30%
1.30%
Add
21 425.00K $27.82M 1.29%
1.29%
Add
22 1.80M $25.78M 1.20%
1.20%
Hold
23 10.14M $25.26M 1.18%
1.18%
Hold
24 2.53M $24.97M 1.16%
1.16%
Add
25 615.40K $24.94M 1.16%
1.16%
Add
26 7.25M $24.49M 1.14%
1.14%
Add
27 172.12K $24.25M 1.13%
1.13%
Hold
28 967.62K $22.94M 1.07%
1.07%
Hold
29 6.53M $21.21M 0.99%
0.99%
Hold
30 750.00K $18.85M 0.88%
0.88%
Hold
31 850.00K $18.59M 0.86%
0.86%
Add
32 1.15M $18.57M 0.86%
0.86%
Reduce
33 300.00K $17.66M 0.82%
0.82%
Hold
34 643.34K $16.42M 0.77%
0.77%
Reduce
35 2.05M $15.86M 0.74%
0.74%
New
36 1.72M $15.62M 0.73%
0.73%
Add
37 850.00K $15.34M 0.71%
0.71%
Reduce
38 30.00K $15.12M 0.70%
0.70%
Reduce
39 875.76K $13.44M 0.63%
0.63%
Hold
40 2.51M $12.96M 0.60%
0.60%
Hold
41 420.00K $12.95M 0.60%
0.60%
Add
42 11.00M $12.05M 0.56%
0.56%
Hold
43 972.00K $11.15M 0.52%
0.52%
Hold
44 450.00K $11.00M 0.51%
0.51%
New
45 3.99M $10.97M 0.51%
0.51%
Reduce
46 760.35K $10.68M 0.50%
0.50%
Reduce
47 2.60M $10.17M 0.47%
0.47%
New
48 175.00K $9.68M 0.45%
0.45%
Add
49 79.40K $9.63M 0.45%
0.45%
Reduce
50 149.78K $9.61M 0.45%
0.45%
Add

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 70% R 70% F1 70% (modelled on 2026-Q2; 7/10 hit)

Low-confidence forecast This fund replaces about 37% of its Top-10 each quarter and backtests at F1 62% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (11 quarters)

Avg precision 62% · recall 62% · F1 62% · avg rank error 3.7 · Top-10 turnover 37%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 40% 40% 40% IMGN · CERE · CBAY · MDGL · XENE · LIANY · ACLX · CLDX · IMVT · TEVA XBI · MRNA · APGE · XENE · MDGL · CRNX · AUTL · CLDX · ACLX · VERA
2024-Q2 60% 60% 60% XBI · MRNA · XENE · APGE · MDGL · CRNX · CLDX · AUTL · INZY · TEVA SPY · XENE · APGE · MDGL · ACLX · CRNX · NRIX · TEVA · CLDX · ALNY
2024-Q3 60% 60% 60% SPY · XENE · APGE · MDGL · ACLX · CRNX · NRIX · ALNY · TEVA · CLDX XENE · FLNA · APGE · NUVL · ACLX · ALKS · MDGL · CRNX · NRIX · VERA
2024-Q4 70% 70% 70% FLNA · XENE · APGE · NUVL · ACLX · ALKS · MDGL · CRNX · NRIX · VERA XBI · XENE · APGE · ACLX · ALKS · TEVA · VRNA · MDGL · CRNX · NUVL
2025-Q1 80% 80% 80% XBI · XENE · APGE · ALKS · ACLX · TEVA · VRNA · MDGL · NUVL · CRNX IWM · XENE · APGE · XBI · VRNA · ACLX · ALKS · NUVL · MDGL · CNTA
2025-Q2 60% 60% 60% IWM · APGE · XBI · XENE · VRNA · ACLX · NUVL · ALKS · MDGL · AMGN VRNA · INSM · XENE · ACLX · BPMC · NUVL · ALKS · PTGX · MDGL · TEVA
2025-Q3 70% 70% 70% VRNA · INSM · XENE · NUVL · ACLX · BPMC · ALKS · PTGX · MDGL · TEVA VRNA · SPY · XENE · MDGL · APGE · ACLX · ALKS · NUVL · ABVX · INSM
2025-Q4 40% 40% 40% VRNA · SPY · XENE · MDGL · APGE · ACLX · ALKS · ABVX · INSM · NUVL XBI · APGE · INSM · ABVX · IBB · VTYX · XENE · PRAX · CYTK · SYRE
2026-Q1 50% 50% 50% XBI · APGE · INSM · ABVX · IBB · VTYX · CYTK · XENE · PRAX · SYRE SPY · APGE · XENE · ERAS · INSM · ROIV · SYRE · CNTA · PRAX · ANAB
2026-Q2 80% 80% 80% SPY · APGE · XENE · ERAS · INSM · ROIV · SYRE · CNTA · ANAB · PRAX ROIV · APGE · SYRE · XENE · ERAS · INSM · PRAX · ORKA · ANAB · AVTX
2026-Q3 ★ 70% 70% 70% ROIV · APGE · SYRE · ERAS · XENE · INSM · ANAB · PRAX · AVTX · ORKA IWM · ROIV · SYRE · XBI · ERAS · TRAX · XENE · INSM · ORKA · AVTX

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-13. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-13 Trading days32 Holdings17 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-13, and will update as prices arrive.

Portfolio return+1.05%Buy & hold
QQQ synthetic benchmark-13.72%Liquidity weighted
Excess return+14.76%vs benchmark
Barra annualised vol27.6%Model estimate
Realised vol27.2%Annualised in window
Weighted beta1.18Raw exposure
Factor / specific risk71% / 29%Share of variance
Top-10 concentration94.2%Of reported value
Portfolio value (start = 100)78.385.492.499.5106.610-0110-2311-13Affinity Asset Advisors, LLCQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)+1.05%Disclosed long book
QQQ synthetic benchmark-13.72%Liquidity-weighted constituents
Model universe, equal weight+0.30%Opportunity-cost reference
Excess return+14.76%Portfolio − benchmark
Arithmetic return sum+1.50%Difference vs compounded is the cross term
Weighted raw beta1.18Weighted holding betas
Realised volatility (annualised)27.25%Daily returns in window
Barra model volatility (annualised)27.58%Factor + specific
Factor share of variance71.4%Barra factors
Specific share of variance28.6%Stock residuals
Reported value$702.3M13F long US equity

2. Return attribution

The +1.50% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 -1.64% -109.0%
Momentum & Growth 3 -3.41% -227.3%
Volatility & Tail Risk 7 -0.27% -17.9%
Industry 12 +8.89% 592.6%
Specific 1 -2.07% -138.3%
Return attribution (style + industry, %)-5.5-2.7+0.0+2.7+5.5Residual Volatility-0.27Size-0.56Amihud Illiquidity-0.60Leverage (Downside Vol)+1.04Non-linear Size+1.31Max Drawdown-1.32Beta+1.58Mid Cap-1.99Historical Volatility-2.70Momentum-3.50Skewness-3.64Other+3.98Health Care+4.91Kurtosis+5.05
Factor Type Exposure Factor return Contribution Share of |return|
Kurtosis Style +0.72 +6.97% +5.05% 336.9%
Health Care Industry +0.60 +8.12% +4.91% 327.3%
Other Industry +0.40 +10.06% +3.98% 265.3%
Beta Style +0.33 +4.85% +1.58% 105.4%
Non-linear Size Style +1.43 +0.91% +1.31% 87.4%
Leverage (Downside Vol) Style -0.57 -1.82% +1.04% 69.2%
Short-term Reversal Style +0.19 +0.79% +0.15% 9.8%
Turnover Style -0.03 -4.77% +0.13% 8.9%
Liquidity Style +0.34 +0.22% +0.07% 4.9%
Growth Style -0.04 +1.57% -0.06% -4.0%
Residual Volatility Style -0.10 +2.66% -0.27% -18.3%
Size Style +0.31 -1.83% -0.56% -37.6%
Amihud Illiquidity Style +1.49 -0.40% -0.60% -40.1%
Max Drawdown Style +0.68 -1.96% -1.32% -88.2%
Mid Cap Style +1.17 -1.69% -1.99% -132.5%
Specific Specific — — -2.07% -138.3%
Historical Volatility Style +0.21 -12.86% -2.70% -179.9%
Momentum Style +1.05 -3.34% -3.50% -233.2%
Skewness Style +0.86 -4.21% -3.64% -243.0%

3. Risk attribution

Annualised volatility is 27.58%; factor risk explains 71.4% of variance and specific risk 28.6%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-30.9-15.5+0.0+15.5+30.9Size-1.31Non-linear Size-1.19Skewness-0.80Kurtosis+1.02Max Drawdown+1.06Liquidity+1.14Amihud Illiquidity+1.66Leverage (Downside Vol)+1.98Mid Cap+5.55Beta+7.26Momentum+9.39Health Care+20.08Other+24.93Specific+28.62
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 28.6% +7.89% 7.9%
Other Industry +0.40 24.9% +6.88% 6.9%
Health Care Industry +0.60 20.1% +5.54% 5.5%
Momentum Style +1.05 9.4% +2.59% 2.6%
Beta Style +0.33 7.3% +2.00% 2.0%
Mid Cap Style +1.17 5.5% +1.53% 1.5%
Leverage (Downside Vol) Style -0.57 2.0% +0.55% 0.6%
Amihud Illiquidity Style +1.49 1.7% +0.46% 0.5%
Liquidity Style +0.34 1.1% +0.32% 0.3%
Max Drawdown Style +0.68 1.1% +0.29% 0.3%
Kurtosis Style +0.72 1.0% +0.28% 0.3%
Short-term Reversal Style +0.19 0.6% +0.16% 0.2%
Historical Volatility Style +0.21 0.5% +0.14% 0.1%
Residual Volatility Style -0.10 -0.3% -0.07% -0.1%
Skewness Style +0.86 -0.8% -0.22% -0.2%
Non-linear Size Style +1.43 -1.2% -0.33% -0.3%
Size Style +0.31 -1.3% -0.36% -0.4%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-0.9-0.10.71.62.4Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size +0.31 +2.10 -1.79
Non-linear Size +1.43 +1.68 -0.24
Mid Cap +1.17 +0.13 +1.05
Beta +0.33 +1.29 -0.97
Momentum +1.05 +0.72 +0.33
Short-term Reversal +0.19 -0.64 +0.83
Residual Volatility -0.10 -0.40 +0.30
Historical Volatility +0.21 +0.86 -0.65
Liquidity +0.34 +0.11 +0.23
Amihud Illiquidity +1.49 +1.16 +0.33
Turnover -0.03 +0.21 -0.23
Growth -0.04 +0.58 -0.62
Leverage (Downside Vol) -0.57 +0.14 -0.71
Skewness +0.86 +0.24 +0.63
Kurtosis +0.72 +0.21 +0.51
Max Drawdown +0.68 -0.08 +0.76

5. Industry allocation & Brinson

Industry allocation (weight, %)-7.414.736.858.981.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsOtherHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -19.18% +4.32% +14.12% -14.12% +14.12%
Other 39.6% 0.0% +1.24% +0.00% +5.27% +0.00% +0.49% +0.49%
Communication Services 0.0% 2.6% +0.00% -15.54% +0.06% +0.41% -0.41% +0.41%
Utilities 0.0% 0.8% +0.00% +11.58% -0.20% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.58% -0.24% -0.13% +0.13% -0.13%
Health Care 60.4% 1.7% -0.25% +9.16% +13.19% -0.16% -5.53% -0.31%
Consumer Discretionary 0.0% 8.8% +0.00% +5.56% -1.66% -0.49% +0.49% -0.49%
Industrials 0.0% 11.1% +0.00% +7.16% -2.27% -0.80% +0.80% -0.80%
Total +18.36% +12.82% -18.02% +13.17%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
IWM ISHARES TR Other 39.57% +1.24% +0.49% New
ROIV ROIVANT SCIENCES LTD Health Care 16.66% +8.09% +1.35% Reduce
INSM INSMED INC Health Care 9.17% +6.15% +0.56% Reduce
MRNA MODERNA INC Health Care 6.86% +15.99% +1.10% Reduce
RVMD REVOLUTION MEDICINES INC Health Care 6.58% -16.06% -1.06% Reduce
ODTX ODYSSEY THERAPEUTICS INC Health Care 3.99% -13.86% -0.55% Add
SGMT SAGIMET BIOSCIENCES INC Health Care 3.55% +3.44% +0.12% Add
PTGX PROTAGONIST THERAPEUTICS INC Health Care 3.45% -7.05% -0.24% Hold
RLAY RELAY THERAPEUTICS INC Health Care 2.19% +0.22% +0.01% Reduce
MDGL MADRIGAL PHARMACEUTICALS INC Health Care 2.15% -15.19% -0.33% Reduce
BEAM BEAM THERAPEUTICS INC Health Care 1.57% -6.63% -0.10% New
CRSP CRISPR THERAPEUTICS AG Health Care 1.38% -23.64% -0.33% Add
NAMS NEWAMSTERDAM PHARMA COMPANY Health Care 0.95% -17.19% -0.16% Hold
TSHA TAYSHA GENE THERAPIES INC Health Care 0.69% -15.81% -0.11% Reduce
NTLA INTELLIA THERAPEUTICS INC Health Care 0.60% -19.57% -0.12% New
AVBP ARRIVENT BIOPHARMA INC Health Care 0.43% -57.03% -0.25% Reduce
GENB GENERATE BIOMEDICINES INC Health Care 0.21% -19.64% -0.04% Reduce
Contribution rank Symbol Sector Weight Return Contribution
1 ROIV Health Care 16.66% +8.09% +1.35%
2 MRNA Health Care 6.86% +15.99% +1.10%
3 INSM Health Care 9.17% +6.15% +0.56%
4 IWM Other 39.57% +1.24% +0.49%
5 SGMT Health Care 3.55% +3.44% +0.12%
6 RLAY Health Care 2.19% +0.22% +0.01%
7 GENB Health Care 0.21% -19.64% -0.04%
8 BEAM Health Care 1.57% -6.63% -0.10%
9 AVBP Health Care 0.43% -57.03% -0.25%
10 CRSP Health Care 1.38% -23.64% -0.33%
11 MDGL Health Care 2.15% -15.19% -0.33%
12 ODTX Health Care 3.99% -13.86% -0.55%
13 RVMD Health Care 6.58% -16.06% -1.06%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-13 (32 trading days), the reported portfolio returned +1.05%, versus -13.72% for the QQQ synthetic benchmark — an excess of +14.76%.
  2. Return attribution: the largest positive style/industry contributions came from Kurtosis +5.05%, Health Care +4.91%, Other +3.98%; the largest drags came from Skewness -3.64%, Momentum -3.50%, Historical Volatility -2.70%. Specific (stock-level) return contributed -2.07%.
  3. Risk attribution: Barra model volatility is 27.58% annualised; factor risk explains 71% of variance and specific risk 29%. The largest factor risk sources are Other 24.9%, Health Care 20.1%, Momentum 9.4%.
  4. Style tilt: size +0.31, momentum +1.05, volatility +0.21, liquidity +0.34; the weighted raw beta is 1.18. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+58.7 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +18.36%, selection +12.82% and interaction -18.02%.
  6. Concentration: the top-10 positions are 94.2% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Affinity Asset Advisors, LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, Affinity Asset Advisors, LLC reported 112 equity positions worth $2.15B in aggregate; its largest disclosed positions were IWM ($277.89M), ROIV ($117.02M), SYRE ($113.88M).

How large is Affinity Asset Advisors, LLC's portfolio?

Affinity Asset Advisors, LLC reported $2.15B of long equity holdings across 112 positions as of 2026-Q3. Top-10 holdings account for 46.3% of reported value.

What is Affinity Asset Advisors, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/affinity-asset-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →